Learn About Transthyretin Amyloid Cardiomyopathy
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Cleveland Clinic Main Campus
Mazen Hanna is a Cardiologist in Cleveland, Ohio. Dr. Hanna has been practicing medicine for over 33 years and is rated as an Elite provider by MediFind in the treatment of Transthyretin Amyloid Cardiomyopathy. His top areas of expertise are Cardiac Amyloidosis, Transthyretin Amyloid Cardiomyopathy, Primary Amyloidosis, Heart Transplant, and Tenotomy.
Brigham And Women's Hospital
Rodney Falk is a Cardiologist in Boston,, Massachusetts. Dr. Falk is rated as an Elite provider by MediFind in the treatment of Transthyretin Amyloid Cardiomyopathy. His top areas of expertise are Cardiac Amyloidosis, Primary Amyloidosis, Transthyretin Amyloidosis, Heart Transplant, and Cardiac Ablation.
Heart RHYTHM Consultants P.C.
Stephen Heitner is a Cardiologist in Portland, Oregon. Dr. Heitner is rated as an Elite provider by MediFind in the treatment of Transthyretin Amyloid Cardiomyopathy. His top areas of expertise are Hypertrophic Cardiomyopathy (HCM), Cardiomyopathy, Transthyretin Amyloidosis, Pacemaker Implantation, and Heart Bypass Surgery.
Summary: Transthyretin amyloidosis (ATTR) is a disease where the normally occurring transthyretin (TTR) protein falls apart and forms amyloid, a sticky plaque- like substance that accumulates in different organs in the body and can cause damage to the organ. There are two ways that the TTR protein can fall apart. One way occurs as a person ages, where the normal TTR protein can fall apart and form amyloid ...
Summary: This study will find out if a new medicine called NNC6019-0001 can help reduce the risk of heart-related death and illness in participants with a condition called transthyretin amyloid cardiomyopathy (ATTR-CM), which affects the heart. Participants will either receive NNC6019-0001 or a placebo (a treatment with no active medicine), and which one they get is decided by chance. Everyone in the study...